Clinical Trial Update: CS-206 in Patients With Sickle Cell Disease [EARLY_Phase 1]

View source ↗

Summary

CS-206 is an investigational drug being evaluated in an early-phase 1 clinical trial for sickle cell disease, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• CS-206

Snippet

Sponsor: CorrectSequence Therapeutics Co., Ltd | Conditions: Sickle Cell Disease | EARLY_Phase 1 | Status: RECRUITING